Arca
Skip to content
Tools
Tools

Peripheral t cell lymphoma

Drug research and approvals for peripheral t cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 152 studies of peripheral t cell lymphoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.

  • Recruiting worldwide: 152
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 152 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 12 of 21

Phase 2 12 of 36

Phase 1 or earlier 12 of 17

How its trials ended

627 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 156 whose ending is known, 38% met their primary endpoint, 6% missed it and 56% stopped early.

  • Ongoing18730%
  • Completed, result not reported16526%
  • Status unknown11919%
  • Met its primary endpoint599%
  • Stopped: other or unclear335%
  • Stopped: enrollment or feasibility254%
  • Stopped: sponsor or business decision183%
  • Missed its primary endpoint102%
  • Stopped: lack of efficacy51%
  • Stopped: safety3<1%
  • Stopped: funding3<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jun 20, 2025An open-label, multicenter, phase 1 trial to evaluate the safety, pharmakonetics, and anti-tumour activity of TLN-121 as a single agent and in combination with…TLN-121 / Cyclophosphamide / Lunsumio (mosunetuzumab) / Columvi (glofitamab) /…Treeline BiosciencesOngoing
Dec 4, 2024A phase 3, randomized, open label study to investigate the efficacy and stafety of itk inhibitor soquelitinib versus physician's choice standard of care…Soquelitinib (CPI-818)Corvus PharmaceuticalsOngoing
Oct 30, 2024Phase 1b, randomized, dose optimization study to assess the anti-tumor activity, safety, and pharmacokinetics of TLN-254 in patients with relapsed or…TLN-254Treeline BiosciencesOngoing
Mar 19, 2024A phase 3, randomized, open-label study comparing the efficacy and safety of the combination of beleodaq-chop or folotyn-cop to the chop regimen alone in newly…Belinostat / PralatrexateAcrotech BiopharmaOngoing
Jun 13, 2018"a phase 2 study of brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (chep-bv) followed by bv consolidation in patients with…AdcetrisBC Cancer, Part of The Provincial Health Services AuthorityOngoing
May 24, 2016A phase I trial of MEDI-570 in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) follicular variant and angioimmunoblastic T-cell lymphoma…MEDI-570 / GlucovisionPrincess Margaret Hospital Phase I ConsortiumClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.